Physician profile
Patrick R Smith
NPI 1093715096
$13,254.34
in general payments reported to CMS, 2019-2025
53 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $2,120 · 2021: $2,644 · 2022: $2,572 · 2023: $2,439 · 2024: $751 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.88 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,644.38 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,198.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,047.46 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $947.85 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $710.36 | 2019-2025 | |
| Novo Nordisk INC | $698.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $501.49 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $474.37 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $467.04 | 2020-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.50 | 2019-2023 | Xifaxan |
| Allergan, INC. | $445.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.71 | 2019-2023 | Jardiance, Stiolto Respimat, Combivent Respimat |
| Merck Sharp & Dohme LLC | $394.08 | 2019-2023 | Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $304.90 | 2022-2023 | Seglentis |
| Gilead Sciences, INC. | $271.49 | 2020-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.